---
title: "MPCSH released its performance for the first three quarters, with a net loss attributable to shareholders of 93.7306 million yuan"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262665110.md"
description: "According to the Zhitong Finance APP, MPCSH released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 2.304 billion yuan, a year-on-year decrease of 19.24%. The net loss attributable to shareholders of the listed company was 93.7306 million yuan. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 109 million yuan"
datetime: "2025-10-24T15:52:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262665110.md)
  - [en](https://longbridge.com/en/news/262665110.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262665110.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/262665110.md) | [English](https://longbridge.com/en/news/262665110.md)


# MPCSH released its performance for the first three quarters, with a net loss attributable to shareholders of 93.7306 million yuan

According to the Zhitong Finance APP, MPCSH (000637.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 2.304 billion yuan, a year-on-year decrease of 19.24%. The net loss attributable to shareholders of the listed company was 93.7306 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 109 million yuan

### 相關股票

- [MPCSH (000637.CN)](https://longbridge.com/zh-HK/quote/000637.CN.md)

## 相關資訊與研究

- [BYD reportedly explores F1 entry to boost global brand appeal](https://longbridge.com/zh-HK/news/278576491.md)
- [Bessent, on safe passage of ships in Strait of Hormuz, says U.S. is on track to get this solved](https://longbridge.com/zh-HK/news/278171367.md)
- [Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China](https://longbridge.com/zh-HK/news/278445287.md)
- [Kainova Therapeutics reports positive phase 1 results for DT‑9081 in advanced solid tumours](https://longbridge.com/zh-HK/news/278526333.md)
- [Vinachem diversifies fertiliser raw material supply](https://longbridge.com/zh-HK/news/278532872.md)